Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54


Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies.

Kayton ML, He M, Zakowski MF, Moreira AL, Lau C, Chou AJ, Merchant M, Merola PR, Wexler LH, La Quaglia MP, Travis WD, Ladanyi M.

J Thorac Oncol. 2010 Nov;5(11):1764-71. doi: 10.1097/JTO.0b013e3181f69f08.


Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M.

Clin Cancer Res. 2012 Nov 15;18(22):6169-77. doi: 10.1158/1078-0432.CCR-11-3265. Epub 2012 Sep 26.


Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, Pao W.

Chest. 2010 Jan;137(1):46-52. doi: 10.1378/chest.09-0325. Epub 2009 Apr 17.


Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111.


Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

D'Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M, Zakowski MF.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):476-80. doi: 10.1016/j.jtcvs.2010.08.026. Epub 2010 Oct 8.


Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.

Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H, Ji H.

J Thorac Oncol. 2010 Aug;5(8):1130-5. doi: 10.1097/JTO.0b013e3181e05016.


EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH.

Korean J Intern Med. 2009 Mar;24(1):48-54. doi: 10.3904/kjim.2009.24.1.43.


Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.


Lesions in patients with multifocal adenocarcinoma are more frequently in the right upper lobes.

Kaneda H, Uemura Y, Nakano T, Taniguchi Y, Saito T, Konobu T, Saito Y.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):627-32. Epub 2012 Jun 24.


Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE; Cancer, Leukemia Group B, Chicago, IL.

J Thorac Oncol. 2010 Sep;5(9):1382-90. doi: 10.1097/JTO.0b013e3181eba657.


Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.

Raparia K, Villa C, Raj R, Cagle PT.

Arch Pathol Lab Med. 2015 Feb;139(2):189-93. doi: 10.5858/arpa.2013-0759-OA. Epub 2014 Apr 2.


Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.

Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M, Hirohashi S.

Cancer Sci. 2007 Jul;98(7):985-91. Epub 2007 Apr 23.


Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.

Onozato ML, Kovach AE, Yeap BY, Morales-Oyarvide V, Klepeis VE, Tammireddy S, Heist RS, Mark EJ, Dias-Santagata D, Iafrate AJ, Yagi Y, Mino-Kenudson M.

Am J Surg Pathol. 2013 Feb;37(2):287-94. doi: 10.1097/PAS.0b013e31826885fb.


Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.

Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.

J Thorac Oncol. 2010 Nov;5(11):1734-40. doi: 10.1097/JTO.0b013e3181f0beca. Erratum in: J Thorac Oncol. 2011 Jun;6(6):1147.


Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan.

Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YT, Chen YR, Huang SF.

J Thorac Oncol. 2010 Aug;5(8):1175-84. doi: 10.1097/JTO.0b013e3181e2f4d6.


Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.

Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M.

Mod Pathol. 2010 Feb;23(2):159-68. doi: 10.1038/modpathol.2009.154. Epub 2009 Oct 23.


Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.

Hata A, Katakami N, Fujita S, Kaji R, Imai Y, Takahashi Y, Nishimura T, Tomii K, Ishihara K.

J Thorac Oncol. 2010 Aug;5(8):1197-200. doi: 10.1097/JTO.0b013e3181e2a2bc.


Lung cancers unrelated to smoking: characterized by single oncogene addiction?

Suda K, Tomizawa K, Yatabe Y, Mitsudomi T.

Int J Clin Oncol. 2011 Aug;16(4):294-305. doi: 10.1007/s10147-011-0262-y. Epub 2011 Jun 8.


Supplemental Content

Support Center